VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CDNA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CDNACareDx, Inc
$78.56$4.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. CDNA
  4. Financial Ratios

CareDx, Inc (CDNA) Financial Ratios

Latest Ratios: P/E Ratio 33.6x · EV/EBITDA 154.8x · ROE -6.3%. (2012–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

CDNA Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$4.1B$1.0B$1.2B$645M$608M$2.4B$3.4B$909M$896M$171M$45M
Enterprise Value$4.0B$965M$1.1B$597M$557M$2.0B$3.3B$876M$832M$188M$51M
P/E Ratio →33.58—23.02————————
P/S Ratio8.162.643.632.301.898.0217.527.1611.703.541.10
P/B Ratio13.813.313.202.471.415.1012.139.189.34—2.25
P/FCF67.5327.8038.41———145.97————
P/OCF96.5523.8931.86———100.73————

P/E links to full P/E history page with 30-year chart

CDNA EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—2.543.372.131.736.9116.926.9010.863.901.26
EV / EBITDA154.84—18.60————————
EV / EBIT———————————
EV / FCF—26.7135.67———140.91————

CDNA Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin67.6%67.6%67.2%63.6%65.1%67.1%67.2%64.2%56.9%55.8%48.0%
Operating Margin-6.6%-6.6%12.2%-72.5%-24.0%-10.0%-11.7%-19.3%-20.3%-42.0%-91.9%
Net Profit Margin-5.6%-5.6%15.7%-67.9%-23.8%-10.3%-9.7%-17.3%-61.1%-114.8%-97.1%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-6.3%-6.3%16.4%-55.0%-17.1%-8.2%-9.9%-22.5%-103.9%-803.5%-160.3%
ROA-4.7%-4.7%11.0%-37.7%-13.8%-6.6%-7.2%-15.6%-43.6%-69.2%-59.6%
ROIC-6.8%-6.8%12.1%-51.4%-22.3%-14.9%-14.9%-37.7%-54.7%-80.8%-133.9%
ROCE-6.9%-6.9%10.3%-47.5%-16.2%-7.5%-10.8%-21.5%-20.5%-53.0%-91.7%

CDNA Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.090.090.070.130.090.050.070.050.00—1.21
Debt / EBITDA——0.47————————
Net Debt / Equity—-0.13-0.23-0.18-0.12-0.70-0.42-0.33-0.67—0.34
Net Debt / EBITDA——-1.43————————
Debt / FCF—-1.09-2.73———-5.05————
Interest Coverage————————-4.21-3.13-13.32

Net cash position: cash ($65M) exceeds total debt ($26M)

CDNA Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio2.862.863.944.025.105.613.952.074.160.620.65
Quick Ratio2.562.563.723.774.855.383.801.893.910.490.52
Cash Ratio1.971.972.923.023.864.513.251.103.310.390.42
Asset Turnover—0.920.680.600.590.520.520.840.590.580.53
Inventory Turnover4.614.615.625.245.835.676.307.566.673.873.87
Days Sales Outstanding—40.9770.6566.4875.2273.5965.7669.1046.5322.5924.87

CDNA Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield3.0%—4.3%————————
FCF Yield1.5%3.6%2.6%———0.7%————
Buyback Yield2.2%8.7%0.0%4.3%0.1%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield2.2%8.7%0.0%4.3%0.1%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$53M$57M$54M$53M$52M$46M$42M$36M$23M$16M

Key Metrics

Growth RegimeExpanding
ProfitabilityWeak
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Volatile quarterly earnings quality

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Priced Against Unproven Earnings

Based on reported figures, CDNA trades at 10.69 times sales and 13.81 times book value with a negative trailing P/E of -196.40, while its forward P/E of 58.66 implies the market is pricing in a sustained earnings recovery that has not yet appeared in reported results.

The price-to-sales multiple of 10.69 sits well above the diagnostics peer group, where Illumina trades at a PEG of 9.24 and a P/E of 39.11, while Natera and Exact Sciences carry negative trailing earnings, suggesting investors are paying for revenue growth rather than current profitability. The gap between the negative trailing P/E and the 58.66 forward P/E indicates that valuation rests almost entirely on expectations that operating margins can expand well beyond the recent 5.8 percent level. Investors should monitor whether reported margins converge toward the implied forecast, since a failure to do so would leave the premium multiple difficult to justify on fundamentals.

Gross Margin Strength Obscured by SG&A Burden

According to reported quarterly figures, CDNA's gross margin reached 71.1 percent in 2026Q3 while operating margin was only 5.8 percent, meaning SG&A absorbs nearly all of the gross profit gained from revenue scaling.

The gross margin in the 66 to 71 percent range points to reasonable unit economics in the diagnostics testing business, but operating margin has swung between roughly negative 16 percent and positive 86 percent, which reflects non-operating and one-time items rather than a steady core earnings base. Net margin of 13.8 percent in 2026Q3 is inflated relative to operating margin, which suggests investors should treat headline net income with caution. Earning power is better judged by operating margin trends than by net margin, and on that basis profitability remains thin relative to the Illumina benchmark of 19.6 percent net margin.

Returns Oscillating Without Sustained Compounding

As reported in financial statements, CDNA's ROIC has swung from negative 3.3 percent to 52.2 percent over recent quarters, indicating that returns on invested capital are episodic and not yet compounding in a consistent direction.

The ROIC pattern is dominated by a few quarters of outsized positive readings, most notably 52.2 percent in 2026Q2, which appear driven by one-time gains rather than improving operating efficiency given the modest operating margins elsewhere in the series. Excluding these spikes, the underlying return profile hovers near low single digits, well below the 16.8 percent ROIC reported by Illumina. Until returns stabilize, the trend should be viewed as non-compounding, and investors should monitor whether ROIC holds above the cost of capital across multiple consecutive quarters.

Minimal Leverage Keeps Solvency Risk Contained

Based on reported figures, CDNA's debt-to-equity ratio of 0.06 in 2026Q3 and debt-to-EBITDA of 1.89 indicate that leverage is negligible relative to the capital base and debt service pressure is low.

The debt-to-equity ratio has declined from 0.12 in 2024Q2 to 0.06 in 2026Q3, a trend that suggests the company has been deleveraging as equity grew through cash accumulation. Interest coverage is not meaningfully reported in most quarters, so a full assessment of debt service comfort is limited, though the low absolute debt load reduces the importance of that gap. Refinancing risk appears limited based on the reported figures, but the analysis is constrained by sparse coverage data.

Headline Returns Likely Flattered by One-Time Items

Based on reported quarterly figures, CDNA's 52.2 percent ROIC and 86 percent operating margin in 2026Q2 contrast sharply with negative readings in adjacent quarters, suggesting the most common reading of peak returns may overstate durable profitability.

Return on invested capital is most often read as a signal of franchise quality, but for a company whose quarterly results swing between large gains and losses, a single peak quarter can dominate averages and trend lines. The sharp reversal from 52.2 percent to 0.5 percent in the following quarter suggests the spike reflects non-recurring gains rather than a repeatable shift in operating efficiency. Investors should monitor trailing four-quarter ROIC and operating margin excluding one-time items before treating the 2026Q2 readings as evidence of sustained earning power.

Download Financial Ratios Data

Includes 30+ ratios · 14 years · Updated daily

Consensus & Technical Research Suite
Open CDNA Terminal

CDNA Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

CDNA — Frequently Asked Questions

Quick answers to the most common questions about buying CDNA stock.

What is CareDx, Inc's P/E ratio?

CareDx, Inc's current P/E ratio is 33.6x. The historical average is 47.8x. This places it at the 50th percentile of its historical range.

What is CareDx, Inc's EV/EBITDA?

CareDx, Inc's current EV/EBITDA is 154.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 21.3x.

What is CareDx, Inc's ROE?

CareDx, Inc's return on equity (ROE) is -6.3%. The historical average is -36.7%.

Is CDNA stock overvalued?

Based on historical data, CareDx, Inc is trading at a P/E of 33.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are CareDx, Inc's profit margins?

CareDx, Inc has 67.6% gross margin and -6.6% operating margin.